Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD study of HEC113995 in healthy subjects
NCT04591301Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mitizodone in major depressive disorder (MDD) (8 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Number of Adverse Events up to 7 days. Started Jul 2019; status: completed.
02
Drugs
mitizodone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04591301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04591301.